Abundance Potential

Assessment scope

Development

Experimental finding that CRISPR-Cas fitness benefits in Pseudomonas aeruginosa vary by phage and are associated with how readily receptor resistance evolves.

Baseline

Isogenic P. aeruginosa PA14 with functional CRISPR-Cas compared with PA14 lacking functional CRISPR-Cas, under the study’s airway-mimicking laboratory conditions.

Population

The PA14 laboratory strain and 26 naturally virulent phages tested individually and in pairs; no patient population was studied.

Geography

In vitro laboratory setting; no geographic population or clinical setting was evaluated.

Target assumptions

Any societal benefit would require the experimental relationships to generalize beyond PA14 and help guide phage selection in relevant treatment settings.

Five dimensions

Human wellbeing

Unknown · The experiments do not establish patient outcomes or other direct effects on human health. Sources: evidence-1803, evidence-1804

Affordability and access

Unknown · The evidence provides no information about treatment costs, affordability, or access.

Reach and fairness

Unknown · The evidence does not establish who would receive any future benefit or whether access would be fair.

Environment and resources

Unknown · The experiments provide no evidence about environmental or resource effects.

Scientific capability

2/4 · The experiments add a meaningful but bounded research basis for understanding how phage identity and the ease of receptor-resistance evolution relate to CRISPR benefit. The finding is limited to a laboratory model, and the proposed binding mechanism remains uncertain; it does not establish a clinical capability. Sources: evidence-1800, evidence-1801, evidence-1802, evidence-1804, evidence-1806

Evidence, confidence and timing

Evidence maturity

Finding: Laboratory. The finding comes from controlled laboratory comparisons of PA14 strains and phages, not from a clinical or deployed application.

Societal benefit: Early speculative. The study suggests ecological and possible treatment-research relevance, but does not demonstrate patient or treatment outcomes.

Confidence: Moderate. Controlled comparisons support the reported experimental pattern, but the evidence is bounded to the tested model and the authors identify unresolved effects and mechanisms.

Conditional time horizon: Unknown. The evidence gives no translational timeline; any societal benefit depends on further validation and application beyond the laboratory model.

Possible benefits

• Could improve scientific understanding of which phage-host interactions make CRISPR immunity more advantageous and inform future phage-treatment research; no treatment benefit is demonstrated. Sources: evidence-1801, evidence-1803

Risks and possible harms

• If the laboratory relationship is overgeneralized into treatment choices, phage selection could be ineffective because CRISPR effects vary by phage; unresolved escape mechanisms add uncertainty. Affected groups: Patients with infections considered for future phage treatment, and researchers or clinicians translating the finding. Sources: evidence-1800, evidence-1806

Distribution and adoption

Who might be excluded

• Patients, other P. aeruginosa strains, and people affected by other pathogens are outside the tested PA14 laboratory model; patient outcomes were not evaluated. Sources: evidence-1803, evidence-1804

Adoption barriers

• Translation requires validation beyond the tested PA14 laboratory conditions and evidence of clinical relevance. Sources: evidence-1803, evidence-1804
• Phage effects differ, and few tested pairs outperformed their most effective individual phage, so future applications would require phage-specific evaluation. Sources: evidence-1800, evidence-1805

Assumptions and conditions that could change the assessment

• The observed relationship between CRISPR benefit and receptor-resistance evolution generalizes to other relevant strains and settings. Sources: evidence-1801, evidence-1804
• Using the finding to guide future phage selection would improve useful outcomes or access; that link has not been demonstrated. Sources: evidence-1803
• Evidence across additional clinically relevant strains and treatment settings showing improved patient outcomes could support scoring human wellbeing and access. Sources: evidence-1803, evidence-1804
• Replication showing the relationship does not generalize, or that other effects explain the comparison, would weaken the finding’s practical relevance. Sources: evidence-1806

Citations

1. evidence-1800 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source
2. evidence-1801 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source
3. evidence-1802 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source
4. evidence-1803 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source
5. evidence-1804 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source
6. evidence-1805 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source
7. evidence-1806 · Resistance mutation supply modulates the benefit of CRISPR immunity against virulent phages in Pseudomonas aeruginosa · R; o; s; a; n; n; a; ; C; .; ; T; .; ; W; r; i; g; h; t · 10.1371/journal.pbio.3004094 · Captured publisher article text · Open source